POP-OUT | CLOSE
 
 
INDOMETHACIN
 
IMN is found in 22 entries
IMN
  •   Chemical Component Summary   Hide
    Name INDOMETHACIN
    Identifiers {1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
    2-[1-(4-chlorophenyl)carbonyl-5-methoxy-2-methyl-indol-3-yl]ethanoic acid
    Formula C19 H16 Cl N O4
    Molecular Weight 357.79 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key CGIGDMFJXJATDK-UHFFFAOYSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00328   (Stereoisomeric match)
    Name Indomethacin
    Groups
    • approved
    • investigational
    Description Indomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway.
    Synonyms
    • {1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
    • 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
    • Aconip
    • Indocin
    • Indometacin
    • Indometacina
    • Indometacine
    • Indometacinum
    • Indomethacin
    [more]
    Brand names
    • Arthrexin
    • Elmetacin
    • Indaflex
    • Indocid
    • Indocin
    • Indolar SR
    • Indomed
    • Indoxen
    • Metindol
    • Mikametan
    • Nu-Indo
    • Reumacide
    • Tivorbex
    [more]
    Affected organism Humans and other mammals
    Indication For moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
    Pharmacology Indomethacin, a NSAIA, with analgesic and antipyretic properties exerts its pharmacological effects by inhibiting the synthesis of prostaglandins involved in pain, fever, and inflammation. Indomethacin inhibits the catalytic activity of the COX enzymes, the enzymes responsible for catalyzing the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway. Indomethacin is known to inhibit two well-characterized isoforms of COX, COX-1 and COX-2, with greater selectivity for COX-1. COX-1 is a constitutively expressed enzyme that is involved in gastric mucosal protection, platelet and kidney function. It catalyzes the conversion of arachidonic acid to prostaglandin (PG) G2 and PGG2 to PGH2. COX-1 is involved in the synthesis pathways of PGE2, PGD2, PDF2a, PGI2 (also known as prostacyclin) and thromboxane A2 (TXA2). COX-2 is constitutively expressed and highly inducible by inflammatory stimuli. It is found in the central nervous system, kidneys, uterus and other organs. It also catalyzes the conversion of arachidonic acid to PGG2 and PGG2 to PGH2. In the COX-2-mediated pathway, PGH2 is subsequently converted to PGE2 and PGI2 (also known as prostacyclin). PGE2 is involved in mediating inflammation, pain and fever. Decreasing levels of PGE2 leads to decreased inflammation.
    Mechanism of action Indomethacin is a prostaglandin G/H synthase (also known as cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. Indomethacin antagonizes COX by binding to the upper portion of the active site, preventing its substrate, arachidonic acid, from entering the active site. Indomethacin, unlike other NSAIDs, also inhibits phospholipase A2, the enzyme responsible for releasing arachidonic acid from phospholipids. Indomethacin is more selective for COX-1 than COX-2, which accounts for its increased adverse gastric effects relative to other NSAIDs. COX-1 is required for maintaining the protective gastric mucosal layer. The analgesic, antipyretic and anti-inflammatory effects of indomethacin occur as a result of decreased prostaglandin synthesis. Its antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
    Route of administration
    • Intravenous
    • Oral
    • Rectal
    Categories
    • Gout Suppressants
    • Anti-Inflammatory Agents, Non-Steroidal
    • Cyclooxygenase Inhibitors
    • Cardiovascular Agents
    • Tocolytic Agents
    ATC-Code
    • M01AB01
    • C01EB03
    AHFS-Code 28:08.04.92
    CAS number 53-86-1
    Targets
    Name Sequence search Pharmacological action Actions
    Prostaglandin G/H synthase 1   Search  unknown inhibitor
    Peroxisome proliferator-activated receptor alpha   Search  unknown agonist
    Peroxisome proliferator-activated receptor gamma   Search  unknown activator
    Prostaglandin G/H synthase 2   Search  yes inhibitor
    Lactoylglutathione lyase   Search  unknown inhibitor
    [more]
     
Ligand Image